ClinicalTrials.gg
Active, not recruitingNCT06854614STAY-LEANUpdated Sep 30, 2026

Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)

A Phase 4 interventional study of Comprehensive weight loss and Enhanced lifestyle changes in Obesity, sponsored by The Cleveland Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by The Cleveland Clinic · Phase 4, Interventional, and Treatment

How we know · 13 judgments

Updated Sep 30, 2026Interventions changedTitle changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
25 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies testing tirzepatide in Obesity — 62 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
39th of 106
150 · median 69
Started
2025
with 33 others
Phase 4
30 of 106
21 open now
Primary completion
2027-04
later than 23 of 78 live
Registered
41st of 106
by date
Lead sponsor
4 of 106
The Cleveland Clinic

Among the 106 studies testing tirzepatide in Obesity, this one is the 39th largest by enrollment, is one of 34 that started in 2025, is one of 30 in phase 4, reaches primary completion later than 23 of the 78 other live ones, and was the 41st registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

62 of the 106 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

57 more — sign in →

By country, each count listing its studies:

All 62 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 25 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

This is a prospective, pragmatic, 21 month, single-center, randomized, 2-phased, open-label, parallel-group trial comparing the use of enhanced lifestyle changes (ELC) in two different therapy: sequential vs continuation of AOM. The ELC consists of a medically supervised and comprehensive weight loss program (Cleveland Clinic's Department of Endocrinology, Diabetes and Metabolism's Integrated Weight Management Program). In the first phase (9 months) of the study, all participants will receive Tirzepatide 15 mg (option #1) or Semaglutide 2.4 mg if Tirzepatide is not tolerated. In the second phase, after completing 9 months of Tirzepatide or Semaglutide, participants will continue ELC and will be randomly assigned to an AOM therapy for another 12 months: group 1 (phentermine-topiramate or naltrexone-bupropion) or continuation of the same therapy of the first 9 months - group 2 (Tirzepatide or Semaglutide)

The primary endpoint will be the percentage weight loss at 21 months compared to weight loss at 9 months. The goal will be to show superiority of the arm receiving ELC plus continuation of Tirzepatide or Semaglutide when compared to the other AOM therapy group (phentermine-topiramate or naltrexone-bupropion). Secondary and exploratory endpoints will include percentage of fat mass loss, lean muscle mass, functional capacity, muscle strength and compliance to enhanced lifestyle changes. IRB approval of the study will be obtained. Informed consent will be obtained.

Read the detailed description

Obesity is the most prevalent disease and affects nearly 40% of adults in the US and it is a major risk factor for several chronic diseases including hypertension, dyslipidemia, T2D, depression, coronary heart disease, stroke, osteoarthritis, obstructive sleep apnea (OSA), fatty liver disease, and some cancers, to name a few. Patients with obesity have an increased risk of all-cause and cardiovascular death. In recognition of the biologic basis and seriousness of obesity, several professional health associations and organizations worldwide recognize obesity as a disease . Obesity is often stigmatized and viewed as a personal choice or lack of willpower, rather than a chronic disease, complex disease that can result from a combination of genetic, environmental, and behavioral factors, including diet and physical activity levels.

Obesity is one of the biggest drivers of preventable chronic diseases and healthcare costs in the United States. Currently, estimates for these costs are $497 billion per year in direct health care costs, and $1.24 trillion in indirect costs due to lost productivity in 2016. In addition, obesity is associated with job absenteeism and with lower productivity while at work costing approximately $4.3 billion annually.

Cleveland Clinic is one of the largest hospital systems in the United States, employing approximately 70,000 individuals, most of whom are enrolled in the Cleveland Clinic's Employee Health Plan for their medical insurance. Of the approximately 70,000 adult employees and their spouses on the Health Plan, approximately 22,000 have obesity, defined by BMI ≥ 30 kg/m2, and more than 8,000 suffer severe obesity (BMI ≥ 35 kg/m2). Cleveland Clinic's Employee Health Plan (EHP) provides employees diagnosed with obesity support for participating in a weight management program (part of our Healthy Choice program). Caregivers and their spouses who participate can improve their health and get up to 30% off their premiums by meeting personalized annual medical, nutrition or fitness goals. In 2022, only 40% of employees with obesity signed up for the Healthy Choice program.

In the US, employers are the ultimate purchasers of health care for the majority (56%) of employees. Recommendations support addressing obesity in the workplace; however, real-world evidence of best practices for chronic weight management in the employer context is still lacking. More specifically, the impact of aggressively managing obesity (i.e., the primary problem) including the use of anti-obesity medications (AOMs) is still poorly studied. In order for medications for chronic weight management to be included in the health care offered to employees, employers have to "opt-in" or deliberately decide to pay for these medications for employees, even when payers have added them to their formulary. Despite the potential benefits of these medications, the high cost may limit their accessibility and effectiveness in managing obesity. Recent studies still show that the use of anti-obesity medications are under prescribed, as only one percent of office-based visits for patients with obesity received a prescription for an AOM. More recently, the coverage of anti-obesity medications is expanding across the country, and many federal and state employers, including Medicaid in some states, are now covering AOM therapy.

AOMs are often required as adjuvant therapy for obesity in combination with lifestyle interventions, especially long-term to avoid weight regain. Weight plateau and regain is due to reduction of total energy expenditure due to lean and fat mass loss, in addition to increased appetite due to metabolic adaptation and is often seen once AOM therapy are stopped. Sustainable caloric restriction is not practical in the long-term due changes in metabolic adaptation, metabolic rate and lean muscle mass. Lifestyle interventions encouraging increased physical activity, some caloric restriction and AOMs are helpful for sustainable weight loss, highlighting the importance of developing effective strategies for weight loss maintenance beyond the initial weight loss. In addition to that, sequential pharmacotherapy has emerged as a promising approach for the treatment of obesity, especially for patients who have not achieved adequate weight loss with initial therapy. The use of multiple medications with different mechanism of action can enhance weight loss by targeting different pathways involving energy balance and appetite regulation. New weight management therapies are promising but costs can be prohibitive and long-term treatment sometimes is not feasible. Findings alternative strategies that can maintain the initial weight loss or avoid weight regain are needed. More research is needed to better understand the safety and efficacy of sequential therapy for the treatment of obesity, particularly for long-term weight loss maintenance. Obesity treatment should also go far beyond achieving weight loss: weight is only one measurement for obesity treatment. Preservation of muscle mass, aerobic fitness and body composition, which have cardiovascular and metabolic implications, are often benefits observed when exercise programs are incorporated into weight loss programs.

Our weight management group has extensive experience treating obesity and has developed novel approaches for obesity management. In one of our previous trials, we found greater weight loss with an employer sponsored weight management program augmented with AOMs vs the weight management program (WMP) alone.24 The proposed trial will afford the opportunity to study the effects of a well-established weight management program based on a strong foundation of lifestyle intervention, leveraging a quality diet and focusing on muscle and strength preservation through exercise, augmented with AOM therapy to control appetite. The lifestyle intervention program in this trial will be administered through shared medical appointments SMAs (monthly for the first 13 months, every other month from month 13 to 21), which is a concept based on the chronic care model that combines group appointments for patients with clinical intervention, consisting of encounters with a nutritionist, exercise physiologist, and endocrinologist/obesity medicine specialist. The pharmacologic interventions under study will use FDA-approved medications for chronic weight management in a sequential fashion, approaches that have not been studied extensively.

Cleveland Clinic provides a unique environment to investigate the impact of a weight-centric program, including the utilization of approved medications for chronic weight management in patients with obesity, in the context of an employer-based weight management program. The use of a pragmatic clinical trial (PCT) design aims to study the effects of a weight management program that includes treatment with medication for chronic weight management in an employer-based real-world setting while employing a prospective comparison between two randomly assigned pharmacologic intervention strategies in employees with obesity.

The main objective of this randomized pragmatic clinical trial is to compare whether switching patients from a highly effective (and more costly) AOM (GLP-1 RA or GIP/GLP-1 dual agonist) to an oral, lower-cost AOM versus continuing the GLP-1 RA or GIP/GLP-1 dual agonist leads to significant and sustainable weight loss, and to evaluate whether a structured weight-management program-focused on healthy diet, exercise, and muscle-mass preservation-provides additional benefits when combined with AOM therapy.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender: men and women
  2. Ethnicity: all ethnic groups
  3. Age: ≥ 25, \< 65 years

5. Obesity, ≥ 30 and BMI \< 45 6. An Employee, or the significant other of an employee, that is covered by the Cleveland Clinic Employee Health Plan

Exclusion criteria

Exclusion Criteria:

  1. Patients with history of diabetes
  2. \<30 mL/min/1.73 m2 (calculated by the Chronic Kidney Disease Epidemiology Collaboration Equation, CKD-EPI)
  3. Current therapy, except for maintenance glucocorticoid therapy of prednisone 5 mg or equivalent
  4. Currently or within the past 6 months receiving an anti-obesity medication, or any other medication used for the primary intent of weight loss
  5. Any condition, unwillingness, or inability, not covered by any of the other exclusion criteria, which, in the study clinician's opinion, might jeopardize the subject's safety or compliance with the protocol
  6. Mental incapacity or language barrier
  7. Pregnancy or plans to become pregnant within the next 2 years
  8. Personal or family history of medullary thyroid carcinoma
  9. Personal or family history of Multiple Endocrine Neoplasia syndrome type 2
  10. previous history of pancreatitis, history of severe liver disease (Cirrhosis), or severe disease of digestive tract
  11. History of congestive heart failure
  12. History of bariatric or metabolic surgery/procedure
  13. Prior participation in the Endocrinology and Metabolism Institutes Integrated Weight Management Program within the past 3 months
  14. for physical activity or significant physical limitation
  15. Smoking
  16. Cardiovascular disease including uncontrolled hypertension, history of arrhythmias or coronary artery disease
  17. History of recurrent kidney stones
  18. History of glaucoma
  19. History of seizure disorders
  20. Uncontrolled lung disease (difficult to control Asthma or )
  21. Medications that affect physical performance (beta-blocker or others)
  22. Uncontrolled thyroid disease
  23. Patients with personal commitments that limit optimal participation
  24. Concurrent use of bupropion or naltrexone or previous intolerance to any of these medic
  25. Previous intolerance to use or allergy to any of the anti-obesity medications approved in this study
  26. History of malabsorptive disorders or cholestasis
  27. Conductive implanted devices (i.e. cardiac pacemaker, cardioverter-defibrillators)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Group 1 AOM

    Comprehensive weight loss Program + Enhanced lifestyle changes + Group 1 AOM sequential therapy

    Other: Comprehensive weight loss · Other: Enhanced lifestyle changes · Drug: Naltrexone-Bupropion · Drug: Phentermine-Topiramate

  • Experimental
    Group 2

    Comprehensive weight loss + Enhanced lifestyle changes + Group 2 Continuation of Therapy

    Other: Comprehensive weight loss · Other: Enhanced lifestyle changes · Drug: Tirzepatide · Drug: Semaglutide (Wegovy®)

Interventions

  • OtherComprehensive weight loss

    Shared Medical Appointments

  • OtherEnhanced lifestyle changes

    Subjects will also be referred to an exercise physiologist for a personalized physical activity program. Physical Activity and Exercise will be discussed during SMAs as well and individually as needed for exercise progression The participants exercise prescription will be individualized based on an initial assessment. Exercise duration and progression will be recommended at the discretion of staff and exercise physiologist. The exercise program will be structured but flexible, which means patients can substitute group exercises with individual exercise if necessary, following the FITT-VP format (frequency, intensity, time, type, volume and progression). Patients can reduce exercise frequency if the duration is prolonged, or intensity is increased. Investigators will encourage patients to use Cleveland Clinic gyms across the enterprise.

  • Medication for chronic weight management (Rx)

    Also known as: Mounjaro

  • DrugNaltrexone-Bupropion

    Medication for chronic weight management (Rx)

    Also known as: Contrave

  • DrugPhentermine-Topiramate

    Drug pages: PhentermineStudies of PhenterminePhentermine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · TopiramateStudies of TopiramateTopiramate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Medication for chronic weight management (Rx)

    Also known as: Qsymia

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Medication for chronic weight management (Rx)

06

What researchers measure

Primary outcomes

  1. Weight change

    Weight change from month 9 month to month 21 in body weight (%) between both arms

    Time frame: month 9 to month 21

Secondary outcomes

  1. Change in body weight %

    Change from baseline to month 9, 15 and 21 in body weight (%)

    Time frame: baseline to month 21

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Apr 2027, 25 months after the start.

Of 190 non-industry phase 4 interventional studies under Obesity, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 25 months is below that.

Counting every sponsor, half of 210 studies reached it within 31 months; a quarter within 15 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Mar 3, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Apr 28, 2027
CompletionEst.
Apr 28, 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Changed Naltrexone-Bupropion Combination→Naltrexone-Bupropion. Added Drug: Tirzepatide·Drug: Semaglutide (Wegovy®); removed Drug: Orlistat. Arm changed Group 2 AOM→Group 2
Sep 30, 2026
Title
Sequential or CombinaTionTherapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Interventions Changed Naltrexone-Bupropion Combination→Naltrexone-Bupropion. Added Drug: Tirzepatide·Drug: Semaglutide (Wegovy®); removed Drug: Orlistat. Arm changed Group 2 AOM→Group 2
    Title Sequential or CombinaTionTherapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06854614
Responsible party
Bartolome Burguera (Institute Chief, The Cleveland Clinic) — Principal investigator
First posted
Mar 3, 2025
Start date
Mar 1, 2025
Primary completion
Apr 28, 2027 (estimated)
Completion
Apr 28, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Bartolome Burguera, M.D
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tirzepatide · Phentermine · Topiramate · Semaglutide

Start the discussion